MED12 and non-small cell lung carcinoma: In this study, through data mining across multiple cohorts (MSKCC, TCGA, Naiyer2015, Hira2018) and a retrospectively collected institutional dataset (N = 295), we identified MED12 mutations as predictive biomarkers for improved survival in ICI-treated NSCLC patients.